Loading...
•
Dec 31, 2024
Nevro Q4 2024 Earnings Report
Nevro reported a decrease in revenue and net loss for the fourth quarter of 2024, with adjusted EBITDA remaining negative.
Key Takeaways
Nevro Corp. reported its fourth-quarter and full-year 2024 financial results, with Q4 2024 worldwide revenue at $105.5 million, a 9.1% decrease year-over-year. The company's net loss for the quarter was $53.1 million, and adjusted EBITDA was negative $5.2 million. The company is in the process of being acquired by Globus Medical.
Worldwide revenue for Q4 2024 was $105.5 million, a 9.1% decrease from Q4 2023.
U.S. revenue decreased by 9.9% to $91.4 million in Q4 2024.
Net loss for Q4 2024 was $53.1 million, compared to $8.981 million in Q4 2023.
Adjusted EBITDA for Q4 2024 was negative $5.2 million, down from positive $8.4 million in Q4 2023.
Revenue by Geographic Location
Forward Guidance
Nevro is not issuing full-year 2025 guidance due to the pending acquisition by Globus Medical.
Positive Outlook
- Pending acquisition by Globus Medical expected to close in Q2 2025.
- Full market release of HFX iQ™ with HFX AdaptivAI™ in November 2024.
- Launch of HFX iQ SCS system in select European countries in January 2025.
- New data published demonstrating significant pain relief for diabetic neuropathy with 10 kHz SCS therapy.
- New data published demonstrating superiority of Nevro1™ SI Joint Fusion System.
Challenges Ahead
- No full-year 2025 guidance issued.
- No earnings conference call or webcast in connection with Q4 2024 results.
- Transaction subject to shareholder and regulatory approvals.
- Potential for various closing conditions not being satisfied or waived.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...